Oropharynx squamous cell carcinoma

This phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…

This study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This phase 3 trial compares two types of radiation therapy for advanced throat cancer: standard photon radiation (IMRT) and newer proton beam therapy (IMPT). The goal is to see if proton therapy causes fewer severe side effects while still controlling the cancer. About 440 patien…

This phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …

This phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…

This phase 2 trial is testing whether people with HPV-related throat cancer can safely receive lower doses of radiation and chemotherapy after surgery, compared with the standard full-intensity approach. The goal is to see if this lighter treatment helps preserve swallowing funct…

This trial tests whether giving radiation to a smaller area of the neck can prevent throat cancer from returning while reducing side effects. People with p16-positive oropharynx cancer (a type linked to HPV) who are getting radiation therapy may be eligible. The goal is to see if…

This study tests a less intense version of standard chemo-radiation for people with HPV-positive throat cancer who have had robotic surgery to remove visible tumors. The goal is to see if the milder treatment works just as well as the standard dose but causes fewer side effects. …

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…

This early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…

This study compares a reduced dose of radiation therapy combined with the immunotherapy drug nivolumab against the standard treatment of full-dose radiation plus cisplatin for early-stage HPV-positive oropharyngeal cancer in non-smokers. About 384 participants are enrolled to see…

This study compares two ways of giving the chemotherapy drug cisplatin alongside radiation for people with advanced head and neck cancer. One group gets a high dose every three weeks, the other gets a lower dose weekly. The goal is to see if the weekly schedule causes fewer side …

This phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…

This phase 2 trial tests whether combining an HPV vaccine (PRGN-2009) with the immunotherapy drug pembrolizumab can strengthen the immune system's attack on HPV-positive oropharyngeal cancer before standard treatment. Sixteen adults with newly diagnosed, HPV-related throat cancer…

This early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…

This study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…

This study tests whether giving an extra dose of radiation to oxygen-poor (hypoxic) areas of head and neck tumors can improve treatment response. About 91 adults with advanced squamous cell cancer of the throat or voice box will receive standard chemo-radiation with or without th…

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This study was designed for people with HPV-positive oropharyngeal cancer who still had signs of the virus in their blood after completing standard treatment. Researchers planned to give an immunotherapy drug called BALSTILIMAB to see if it could clear the virus and improve long-…

This study tests whether different drug combinations can improve survival and reduce side effects for people with intermediate or high-risk oropharyngeal (throat) cancer. About 785 participants will receive one of several experimental treatments alongside standard chemoradiothera…

This study tests a shorter, more intense course of radiation therapy (hypofractionated IMRT) given after surgery for head and neck cancer. The goal is to see if it is safe and if it can help patients maintain better swallowing function compared to the standard longer radiation sc…

This study tests two experimental vaccines (HB-201 and HB-202) given with standard chemotherapy drugs (carboplatin and paclitaxel) to people with HPV16-positive oropharyngeal cancer. The goal is to see if this combination can shrink tumors enough to allow less intensive follow-up…

This early-stage trial tests whether injecting a person's own muscle cells into the tongue can safely improve swallowing problems caused by cancer treatment. The study involves 18 adults who had surgery, chemo, or radiation for oropharyngeal cancer at least two years ago. Researc…

This study tests whether a much lower dose of radiation (30 Gy) combined with standard chemotherapy works as well as the usual high dose (70 Gy) for people with HPV-positive throat cancer. The goal is to reduce long-term side effects while still controlling the cancer. About 316 …

This study compares a lower dose of radiation to the standard dose for people with HPV-positive throat cancer. The goal is to see if the lower dose can control the cancer just as well while causing fewer side effects. The trial involves 23 participants with advanced but non-sprea…

This study looks at people with HPV-positive throat cancer that has spread but can still be removed with surgery. After surgery, some patients get the usual high-dose radiation plus chemo, while others get a lower dose. The goal is to see if the lower dose works just as well and …

This study looks at whether giving a lower dose of radiation after robotic surgery can help people with HPV-positive throat cancer have fewer side effects, like trouble swallowing, while still controlling the cancer. About 33 adults with this type of cancer will receive the reduc…

This phase 2 trial compares standard treatment (radiation plus chemotherapy drug cisplatin) against two experimental arms using the immunotherapy drug durvalumab with radiation, followed by either durvalumab alone or durvalumab plus another immunotherapy, tremelimumab. The study …

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…

This study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…

This study tests an oral drug called APG-157 given before standard treatment (surgery or radiation) for people with newly diagnosed head and neck cancer. The goal is to see if the drug can shrink tumors and improve outcomes. About 24 adults with early to advanced stage cancer wil…

This study tests if a person's own muscle cells, grown in a lab and injected into the tongue, can safely improve swallowing problems caused by head and neck cancer treatment. About 66 adults who finished cancer treatment at least 2 years ago and still have moderate swallowing tro…

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…

This study is testing a blood test that looks for HPV DNA in the blood of people treated for HPV-positive oropharyngeal cancer. The goal is to see if the test can find cancer recurrence earlier than standard follow-up methods. About 150 participants are being followed after treat…

This study tests a surgical technique called tongue base mucosectomy, combined with detailed tissue analysis, to find the original site of head and neck cancers that have spread to lymph nodes but have no known primary source. About 100 patients will undergo this procedure, and r…

This study is testing whether a blood test called NavDx can find HPV-related oropharyngeal cancer early by looking for HPV DNA in the blood. Researchers are enrolling adults aged 45 and older with multiple sexual partners who have no history of this cancer. Participants give bloo…

This study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…

This early-phase study tests the safety of combining the drug tolinapant with radiation therapy for people with head and neck cancer that has spread locally but hasn't been treated yet. Participants are those who cannot receive the standard chemotherapy drug cisplatin. The goal i…

This trial tests Gelclair, a mouth rinse that forms a protective coating over the mouth's lining, to see if it eases the painful mouth sores (oral mucositis) caused by radiation therapy for head and neck cancer. The study enrolls adults with squamous cell carcinoma who will recei…

This phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…

This study compares standard in-person follow-up care with telemedicine (phone or video visits) for people who have finished treatment for HPV-related throat cancer and show no signs of cancer on scans. The goal is to see which approach better maintains quality of life, detects a…

This study looks at whether people with throat cancer on one side of the neck can safely receive radiation to only that side, instead of both sides. The goal is to reduce side effects from unnecessary radiation. About 8 participants with early-stage HPV-related tonsil or tongue b…

This study compares two treatments for early-stage throat cancer: robotic surgery (TORS) or radiation therapy (IMRT). It looks at which one leads to better swallowing function and overall quality of life. About 138 adults with HPV-related throat cancer are taking part. The goal i…

This study talks to people living with HIV from diverse backgrounds to learn what helps or hinders them from getting oral health care and cancer prevention. Researchers will hold focus groups and use questionnaires to understand barriers and gather ideas for improvement. The goal…

This study investigates whether head and neck cancers caused by HPV have different genetic profiles compared to those linked to alcohol and tobacco use. By analyzing tumor biopsies, researchers aim to identify genetic markers that could predict how well a patient responds to chem…

This study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast t…

This study looks at whether a blood test that finds HPV DNA can spot throat cancer coming back after treatment, possibly earlier than usual scans. Researchers will follow 200 patients with HPV-positive oropharyngeal cancer to see how accurate the test is. The goal is to improve m…